Hims & Hers, Novo Nordisk Weight-Loss Drug Deal Ends Legal Feud, Stock Soars

Novo Nordisk Partners with Hims & HersNovo Nordisk has decided to sell its weight-loss drug through Hims & Hers' telehealth platform, following a lawsuit over patent violations regarding a compounded version of semaglutide products.In February, Hims & Hers Health agreed to acquire Eucalyptus, a digital health leader, which is expected to enhance Hims & Hers' international presence.Hims and Hers 2026 Guidance Below ExpectationsHims & Hers Health reported fourth-quarter revenue of $617.82 million, falling sho ...